Remove 2018 Remove Clinic Remove Medical Remove Relationship
article thumbnail

Episode 262: Anti-Racism in Medicine Series – Episode 18 – Remedying Health Inequities Driven by the Carceral System

The Clinical Problem Solvers

Our guests remind us to think critically about our role in the carceral system and in imposing systems of control and punishment within clinical settings. Correctional officers act as gatekeepers, deciding who does and does not need medical care.

article thumbnail

Telemedicine and the Prescribing of Controlled Substances After the End of The Covid-19 Pandemic Emergency: DEA Announces Two Significant Proposed Rules: Read the Summary Below, But Learn All the Details and More at HPM’s Webinar on March 23, 2023 (Details Forthcoming….)

FDA Law Blog

The Ryan Haight Act was enacted to address the legal “grey area” in which prescribers and pharmacies operated via the creation of two new statutory requirements: 1) the at least one “in-person” medical evaluation requirement for prescribing practitioners, 21 U.S.C. § 829(e); and 2) the modified registration requirement for online pharmacies.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Episode 120: Antiracism in Medicine Series Episode 1 – Racism, Police Violence, and Health

The Clinical Problem Solvers

Trainees may use this foundation to question how this might impact their medical education and think about this educational legacy may be reformed through curricular and structural changes at their institutions. Applying a critical race lens to relationship-centered care in pregnancy and childbirth: An antidote to structural racism.

article thumbnail

District Court Interprets EKRA

FDA Law Blog

Wasserstein — “EKRA” refers to the Eliminating Kickbacks in Recovery Act, which was part of the Substance Use – Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018. EKRA is codified at 18 U.S.C. § 220 and was described on HP&M’s blog here. 18 U.S.C. § 18 U.S.C. § 18 U.S.C. §

article thumbnail

Rethinking Opioid Conversions: Mary Lynn McPherson and Drew Rosielle

GeriPal

It depends on the clinical situation. So, every single [inaudible 00:05:10] there is per the table, in an equianalgesic relationship to one another. Drew: The problem with equianalgesic tables is that every one of those relationships is fixed and bidirectional. Eric: All right. Is that the way the tables are structured?

IT 139
article thumbnail

Critics Suggest FDA Approving Aduhelm Will Erode the “Public Trust”: What About Patients’ Trust?

FDA Law Blog

I have witnessed it inform whether clinical trial results are clinically meaningful (or not) as well as the selection and even development of primary endpoints. Cavazzoni lays out is the traditional way in which patients have informed drug benefit-risk decision-making: by setting the “clinical context” of the disease.

article thumbnail

District Court Interprets EKRA

FDA Law Blog

Wasserstein — “EKRA” refers to the Eliminating Kickbacks in Recovery Act, which was part of the Substance Use – Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018. EKRA is codified at 18 U.S.C. § 220 and was described on HP&M’s blog here. 18 U.S.C. § 18 U.S.C. § 18 U.S.C. §